Avani D Rao1, Elizabeth A Sugar2, Daniel T Chang3, Karyn A Goodman4, Amy Hacker-Prietz1, Lauren M Rosati1, Laurie Columbo3, Eileen O'Reilly5, George A Fisher6, Lei Zheng7, Jonathan S Pai8, Mary E Griffith1, Daniel A Laheru7, Christine A Iacobuzio-Donahue5, Christopher L Wolfgang9, Albert Koong3, Joseph M Herman10. 1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Biostatistics and Epidemiology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Medical Oncology, Stanford University School of Medicine, Stanford, California. 7. Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 8. University of California at San Francisco School of Medicine, San Francisco, California. 9. Department of Surgical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 10. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: joe@jhmi.edu.
Abstract
PURPOSE: We previously reported clinical outcomes and physician-reported toxicity of gemcitabine and hypofractionated stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC). Here we prospectively investigate the impact of gemcitabine and SBRT on patient-reported quality of life (QoL). METHODS AND MATERIALS: Forty-nine LAPC patients received 33 Gy SBRT (6.6 Gy daily fractions) upfront or after ≤3 doses of gemcitabine (1000 mg/m2) followed by gemcitabine until progression. European Organization for Research and Treatment of Cancer QoL core cancer (QLQ-C30) and pancreatic cancer-specific (European Organization for Research and Treatment of Cancer QLQ-PAN26) questionnaires were administered to patients pre-SBRT and at 4 to 6 weeks (first follow-up [1FUP]) and 4 months (2FUP) post-SBRT. Changes in QoL scores were deemed clinically relevant if median changes were at least 5 points in magnitude. RESULTS: Forty-three (88%) patients completed pre-SBRT questionnaires. Of these, 88% and 51% completed questionnaires at 1FUP and 2FUP, respectively. There was no change in global QoL from pre-SBRT to 1FUP (P = .17) or 2FUP (P > .99). Statistical and clinical improvements in pancreatic pain (P = .001) and body image (P = .007) were observed from pre-SBRT to 1FUP. Patients with 1FUP and 2FUP questionnaires reported statistically and clinically improved body image (P = .016) by 4 months. Although pancreatic pain initially demonstrated statistical and clinical improvement (P = .020), scores returned to enrollment levels by 2FUP (P = .486). A statistical and clinical decline in role functioning (P = .002) was observed in patients at 2FUP. CONCLUSIONS: Global QoL scores are not reduced with gemcitabine and SBRT. In this exploratory analysis, patients experience clinically relevant short-term improvements in pancreatic cancer-specific symptoms. Previously demonstrated acceptable clinical outcomes combined with these favorable QoL data indicate that SBRT can be easily integrated with other systemic therapies and may be a potential standard of care option in patients with LAPC.
PURPOSE: We previously reported clinical outcomes and physician-reported toxicity of gemcitabine and hypofractionated stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC). Here we prospectively investigate the impact of gemcitabine and SBRT on patient-reported quality of life (QoL). METHODS AND MATERIALS: Forty-nine LAPC patients received 33 Gy SBRT (6.6 Gy daily fractions) upfront or after ≤3 doses of gemcitabine (1000 mg/m2) followed by gemcitabine until progression. European Organization for Research and Treatment of Cancer QoL core cancer (QLQ-C30) and pancreatic cancer-specific (European Organization for Research and Treatment of Cancer QLQ-PAN26) questionnaires were administered to patients pre-SBRT and at 4 to 6 weeks (first follow-up [1FUP]) and 4 months (2FUP) post-SBRT. Changes in QoL scores were deemed clinically relevant if median changes were at least 5 points in magnitude. RESULTS: Forty-three (88%) patients completed pre-SBRT questionnaires. Of these, 88% and 51% completed questionnaires at 1FUP and 2FUP, respectively. There was no change in global QoL from pre-SBRT to 1FUP (P = .17) or 2FUP (P > .99). Statistical and clinical improvements in pancreatic pain (P = .001) and body image (P = .007) were observed from pre-SBRT to 1FUP. Patients with 1FUP and 2FUP questionnaires reported statistically and clinically improved body image (P = .016) by 4 months. Although pancreatic pain initially demonstrated statistical and clinical improvement (P = .020), scores returned to enrollment levels by 2FUP (P = .486). A statistical and clinical decline in role functioning (P = .002) was observed in patients at 2FUP. CONCLUSIONS: Global QoL scores are not reduced with gemcitabine and SBRT. In this exploratory analysis, patients experience clinically relevant short-term improvements in pancreatic cancer-specific symptoms. Previously demonstrated acceptable clinical outcomes combined with these favorable QoL data indicate that SBRT can be easily integrated with other systemic therapies and may be a potential standard of care option in patients with LAPC.
Authors: Albert C Koong; Erin Christofferson; Quynh-Thu Le; Karyn A Goodman; Anthony Ho; Timothy Kuo; James M Ford; George A Fisher; Ralph Greco; Jeffrey Norton; George P Yang Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: Joseph M Herman; Aaron T Wild; Hao Wang; Phuoc T Tran; Kenneth J Chang; Gretchen E Taylor; Ross C Donehower; Timothy M Pawlik; Mark A Ziegler; Hongyan Cai; Dionne T Savage; Marcia I Canto; Jason Klapman; Tony Reid; Raj J Shah; Sarah E Hoffe; Alexander Rosemurgy; Christopher L Wolfgang; Daniel A Laheru Journal: J Clin Oncol Date: 2013-01-22 Impact factor: 44.544
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Pablo E Serrano; Joseph M Herman; Kent A Griffith; Mark M Zalupski; Edward J Kim; Tanios S Bekaii-Saab; Edgar Ben-Josef; Laura A Dawson; Jolie Ringash; Alice C Wei Journal: Int J Radiat Oncol Biol Phys Date: 2014-08-04 Impact factor: 7.038
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Matthew H G Katz; Fang-Shu Ou; Joseph M Herman; Syed A Ahmad; Brian Wolpin; Robert Marsh; Spencer Behr; Qian Shi; Michael Chuong; Lawrence H Schwartz; Wendy Frankel; Eric Collisson; Eugene J Koay; JoLeen M Hubbard; James L Leenstra; Jeffrey Meyerhardt; Eileen O'Reilly Journal: BMC Cancer Date: 2017-07-27 Impact factor: 4.430
Authors: Roman O Kowalchuk; David Hillman; Thomas B Daniels; Carlos E Vargas; Jean-Claude M Rwigema; William W Wong; Bradley J Stish; Amylou C Dueck; Richard Choo Journal: Clin Transl Radiat Oncol Date: 2021-09-15
Authors: Colin S Hill; Lauren M Rosati; Chen Hu; Wei Fu; Shuchi Sehgal; Amy Hacker-Prietz; Christopher L Wolfgang; Matthew J Weiss; Richard A Burkhart; Ralph H Hruban; Ana De Jesus-Acosta; Dung T Le; Lei Zheng; Daniel A Laheru; Jin He; Amol K Narang; Joseph M Herman Journal: Ann Surg Oncol Date: 2022-02-07 Impact factor: 5.344
Authors: Alex B Blair; Lauren M Rosati; Neda Rezaee; Georgios Gemenetzis; Lei Zheng; Ralph H Hruban; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Joseph M Herman; Jin He Journal: Surgery Date: 2018-03-12 Impact factor: 4.348